The 29E.2A3 monoclonal antibody reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L1 is expressed on T lymphocytes, B lymphocytes, NK cells, dendritic cells, as well as IFNγ stimulated monocytes, epithelial cells and endothelial cells. PD-L1 binds to its receptor, PD-1, found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Engagement of PD-L1 with PD-1 leads to inhibition of TCR-mediated T cell proliferation and cytokine production. PD-L1 is thought to play an important role in tumor immune evasion. Induced PD-L1 expression is common in many tumors and results in increased resistance of tumor cells to CD8 T cell mediated lysis. The 29E.2A3 antibody has been shown to block the binding of PD-1-Ig to PD-L1.

產品名稱:InVivoMab anti-human PD-L1 (B7-H1)

反應種屬:human

宿主來源:mouse

實驗應用:in vitro PD-L1 blockade, Functional assays, Immunohistochemistry (frozen), Flow cytometry

同種型:IgG2b, κ

免疫原:Full length human PD-L1

克隆性:Monoclonal

克隆號:29E.2A3

產品濃度:Lot specific,typically between 4-11 mg/ml

保存溫度:Undiluted at 4°C in the dark

運輸溫度:Ship with adequate amount of blue ice to ensure the product remains at 4°C for the duration of transit

預期分子量:150 kDa

產品形式:液體

有效期:One year from the date of receipt if stored as recommended

產地:美國

如需購買或咨詢Bioxcell公司的產品，請聯系Bioxcell*代理商欣博盛生物